Study Aims to Compare the Use of Systemic Steroids, to the Combination of Systemic Steroids and Methotrexate and to the Combination of Systemic Steroids With Methotrexate and Mycophenolate Mofetil in the Treatment of Idiopathic Granulomatous Mastitis and to Show Response on Subsequent US Examination
Comparison of Systemic Steroids, Versus Combined Therapy (Systemic Steroids With Methotrexate) Versus Triple Therapy (Systemic Steroids, Methotrexate and Mycophenolate Mofetil) in the Treatment of Idiopathic Granulomatous Mastitis: Imaging Findings and Clinical Outcomes
The present study aims to compare the use of systemic steroids, to the combination of systemic steroids and methotrexate and to the combination of systemic steroids with methotrexate and mycophenolate mofetil in the treatment of idiopathic granulomatous mastitis. Also, this study aims to show the response to medical treatment on subsequent US examinations.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mohannad Aly Fayed, Lecturer
- Phone Number: 00201009373070
- Email: dr.mohannad.fayed@gmail.com
Study Locations
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypt, 11087
- Recruiting
- Kasr Al Ainy School of Medicine
-
Contact:
- Faculty of Medicine Cairo University
- Phone Number: 0020223641088
- Email: website@kasralainy.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histopathological evidence of IGM.
Exclusion Criteria:
- Malignancy. Pregnancy Lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: one (Monotherapy)
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis |
Systemic prednisolone at an initial dose of 30 mg/day |
|
Experimental: two (Double Therapy)
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis |
Systemic prednisolone at an initial dose of 30 mg/day Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week). |
|
Experimental: Three (Triple Therapy)
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis |
Systemic prednisolone at an initial dose of 30 mg/day Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week). Systemic prednisolone (30 mg/day), methotrexate (25 mg/week with folic acid), and mycophenolate mofetil (1g/day in divided doses)." |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete Response
Time Frame: 6 months
|
Defined as achieving both complete clinical and radiologic remission at 6 months |
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- N-158-2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.